Serum TGF-β1 and SMAD3 levels are closely associated with coronary artery disease

BMC Cardiovascular Disorders

Congxin Huang²  Huailong Wang¹  Bo Li¹  Xiaoxin Gao¹  Jianfeng Zhong¹  Wenjiang Chen¹  Wei Lei¹  Can Chen¹ 

[1] Department of Cardiovascular Medicine, The Affiliated Hospital of Guangdong Medical College, Zhanjiang 524000, China;Department of Cardiovascular Medicine, Renmin Hospital of Wuhan University, Wuhan 430060, China

关键词: Biomarkers;    Human;    SMAD3 protein;    TGF-β1;    Coronary artery disease;   

Others  :  855424
DOI  :  10.1186/1471-2261-14-18

 received in 2013-10-23, accepted in 2014-02-11,  发布年份 2014

【 摘 要 】

Background

Coronary artery disease (CAD) is one of the most common diseases leading to mortality and morbidity worldwide. There is considerable debate on whether serum transforming growth factor β1 (TGF-β1) levels are associated with long-term major adverse cardiovascular events in patients with CAD, and to date, no study has specifically addressed levels in patients with different degrees of CAD severity.

Methods

Serum TGF-β1 and mothers against decapentaplegic homolog 3 (SMAD3) concentrations were evaluated in 279 patients with CAD and 268 controls without CAD. The clinical and biochemical characteristics of all subjects were also determined and analyzed.

Results

TGF-β1 and SMAD3 concentrations in CAD patients were significantly higher than those in the controls. The serum TGF-β1 level in acute myocardial infarction (AMI) was significantly higher than that in both stable angina pectoris (SAP) and unstable angina pectoris (UAP) (p < 0.05), while there was no marked difference between levels in SAP and UAP (p > 0.05). SMAD3 levels showed no obvious difference among AMI, SAP, and UAP. TGF-β1 and SMAD3 are potential biomarkers for CAD, and may be more accurate than Lpa, ApoA1, uric acid, BUN, or triglycerides (TG).

Conclusions

Serum TGF-β1 and SMAD3 levels are closely associated with CAD, and may become useful biomarkers for diagnosis and risk stratification.

【 授权许可】

   
2014 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, et al.: American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119:480-486.
• [2]Minino AM: Death in the United States, 2009. NCHS Data Brief 2011, 64:1-8.
• [3]World Health Organization Cardiovascular Diseases (CVDs): Who Fact Sheet. 2011.
• [4]Kathiresan S, Srivastava D: Genetics of human cardiovascular disease. Cell 2012, 148:1242-1257.
• [5]Stylianou IM, Bauer RC, Reilly MP, Rader DJ: Genetic basis of atherosclerosis: insights from mice and humans. Circ Res 2012, 110:337-355.
• [6]Tayebi N, Ke T, Foo JN, Friedlander Y, Liu J, Heng CK: Association of single nucleotide polymorphism rs6903956 on chromosome 6p24.1 with coronary artery disease and lipid levels in different ethnic groups of the Singaporean population. Clin Biochem 2013, 46:755-759.
• [7]Sugamura K, Keaney JF Jr: Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 2011, 51:978-992.
• [8]Tousoulis D, Kampoli AM, Papageorgiou N, Androulakis E, Antoniades C, Toutouzas K, Stefanadis C: Pathophysiology of atherosclerosis: the role of inflammation. Curr Pharm Des 2011, 17:4089-4110.
• [9]Schaan BD, Quadros AS, Sarmento-Leite R, De Lucca G, Jr BA, Bertoluci M: 'Correction:' Serum transforming growth factor beta-1 (TGF-beta-1) levels in diabetic patients are not associated with pre-existent coronary artery disease. Cardiovasc Diabetol 2007, 6:19. BioMed Central Full Text
• [10]Grainger DJ: TGF-beta and atherosclerosis in man. Cardiovasc Res 2007, 74:213-222.
• [11]Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL: Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000, 275:36803-36810.
• [12]Caraci F, Battaglia G, Busceti C, Biagioni F, Mastroiacovo F, Bosco P, Drago F, Nicoletti F, Sortino MA, Copani A: TGF-beta 1 protects against Abeta-neurotoxicity via the phosphatidylinositol-3-kinase pathway. Neurobiol Dis 2008, 30:234-242.
• [13]Edlin RS, Tsai S, Yamanouchi D, Wang C, Liu B, Kent KC: Characterization of primary and restenotic atherosclerotic plaque from the superficial femoral artery: potential role of Smad3 in regulation of SMC proliferation. J Vasc Surg 2009, 49:1289-1295.
• [14]Miyazawa K, Shinozaki M, Hara T, Furuya T, Miyazono K: Two major Smad pathways in TGF- superfamily signalling. Genes Cell 2002, 7:1191-1204.
• [15]Xu F, Lin SH, Yang YZ, Guo R, Cao J, Liu Q: The effect of curcumin on sepsis-induced acute lung injury in a rat model through the inhibition of the TGF-β1/SMAD3 pathway. Int Immunopharmacol 2013, 16:1-6.
• [16]Derynck R, Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
• [17]Zhu Y, Culmsee C, Klumpp S, Krieglstein J: Neuroprotection by transforming growth factor-beta1 involves activation of nuclear factor-kappaB through phosphatidylinositol-3-OH kinase/Akt and mitogen-activated protein kinase-extracellular-signal regulated kinase1,2 signaling pathways. Neuroscience 2004, 123:806-897.
• [18]Goel SA, Guo LW, Shi XD, Kundi R, Sovinski G, Seedial S, Liu B, Kent KC: Preferential secretion of collagen type 3 versus type 1 from adventitial fibroblasts stimulated by TGF-β/Smad3-treated medial smooth muscle cells. Cell Signal 2013, 25:9559-9560.
• [19]Dobaczewski M, Chen W, Frangogiannis NG: Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol 2011, 51:600-606.
• [20]Bujak M, Frangogiannis NG: The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 2007, 74:184-195.
• [21]Liu B, Zhang YM: Study on risk factors of premature coronary artery disease. Chin J Cardiovasc Res 2009, 7:629-632.
• [22]Lin WT, Wu XN, Zhu PP, Zhang ZF, Chen J: Studies on anti-tumor activities of enteromorpha chlorella growth factor in experimental liver cancer and its mechanism. J Fujian Med Univ 2009, 43:227-230.
• [23]Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A: The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med 1995, 1:74-79.
• [24]Crook R, Leatham EW, Salomone OA, Hossein-Nia M, Grainger DJ, Kaski JC: Plasma levels of active transforming growth factor-beta are reduced in patients with three vessel coronary artery disease. Heart 1996, 75:79.
• [25]Tashiro H, Shimokawa H, Yamamoto K, Momohara M, Tada H, Takeshita A: Altered plasma levels of cytokines in patients with ischemic heart disease. Coron Artery Dis 1997, 8:143-147.
• [26]Li CG, Bethell H, Wilson PB, Bhatnagar D, Walker MG, Kumar S: The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis 2000, 152:249-256.
• [27]Batuman O, Go D, Clark LT, Smith EL, Clements P, Feit A, Lederer D: Relationship between cytokine levels and coronary artery disease in women. Heart Dis 2001, 3:80-84.
• [28]Border WA, Ruoslahti E: Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992, 90:1-7.
• [29]Tashiro H, Shimokawa H, Sadamatu K, Yamamoto K: Prognostic significance of plasma concentrations of transforming growth factor-beta in patients with coronary artery disease. Coron Artery Dis 2002, 13:139-143.
• [30]Stefoni S, Cianciolo G, Donati G, Dormi A, Silvestri MG, Coli L, De Pascalis A, Iannelli S: Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002, 61:324-335.
• [31]Os I, Djurovic S, Seljeflot I, Berg K: Transforming growth factor (TGF)-beta1 inversely related to vascular cell adhesion molecule-1 in postmenopausal women with coronary artery disease. A possible mechanism for the putative cardioprotective role of TGF-beta1? J Intern Med 2002, 251:223-227.
• [32]Wen HH, Bai P, Niu LJ, Li YD: The influence of serum uric acid on acute myocardial infarction and its predicative value. Acta Acad Med Nei Mongol 2006, 28:27-31.